Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WIGRETTES vs ERGOMAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.
Ergotamine acts as a partial agonist at serotonin 5-HT1B and 5-HT1D receptors, causing vasoconstriction of cranial blood vessels. It also inhibits norepinephrine reuptake and has alpha-adrenergic blocking activity.
Smoking cessation therapy,Relief of nicotine withdrawal symptoms
Abortive treatment of acute migraine headaches with or without aura,Cluster headache
1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.
Ergotamine tartrate 1-2 mg sublingually or orally at onset of migraine, then 1-2 mg every 30 minutes as needed, maximum 6 mg per attack and 10 mg per week.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in moderate renal impairment.
Terminal elimination half-life is approximately 2-3 hours for ergotamine, but clinical effects may persist longer due to active metabolites (e.g., ergotamine's half-life is 2.4 hours; metabolites have half-lives up to 10 hours).
Primarily hepatic via CYP2A6 and CYP2B6; also metabolized by aldehyde oxidase and N-glucuronidation.
Primarily hepatic via CYP3A4; minor contributions from CYP2D6. Undergoes extensive first-pass metabolism.
Renal excretion of unchanged drug accounts for 50-60% of the dose; biliary/fecal elimination accounts for 20-30%; remainder metabolized.
Primarily hepatic metabolism with extensive biliary excretion; less than 5% excreted unchanged in urine. Fecal elimination accounts for approximately 30-40% of the dose as metabolites.
90-95% bound to albumin and alpha-1-acid glycoprotein.
90-95% bound to plasma proteins, primarily albumin.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution.
Approximately 0.4 L/kg (16-18 L in adults), indicating moderate tissue distribution.
Oral bioavailability is 60-80%; intramuscular bioavailability is 90-100%.
Sublingual: ~40-50%; Oral: <10% due to extensive first-pass metabolism; Rectal: ~25-30%.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
GFR > 30 m L/min: No adjustment. GFR 10-30 m L/min: Caution; reduce dose by 50%. GFR < 10 m L/min: Contraindicated.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 1 mg maximum twice daily. Child-Pugh Class C: Avoid use (not recommended).
Child-Pugh A: Caution; reduce dose by 50%. Child-Pugh B: Contraindicated. Child-Pugh C: Contraindicated.
Not approved for patients under 18 years of age.
Not recommended for children under 12 years. Pediatric use not established; avoid use.
No specific dose adjustment; monitor for adverse effects due to potential age-related decreased renal function.
Elderly patients are more sensitive to vasoconstriction; use lower initial dose (e.g., 1 mg) and monitor for adverse effects.
None
Serious and/or life-threatening peripheral ischemia and vasospasm have been associated with the concomitant use of ergotamine with potent CYP3A4 inhibitors including protease inhibitors, macrolide antibiotics, and azole antifungals.
Risk of nicotine toxicity if used while smoking; caution in cardiovascular disease, hypertension, diabetes, hyperthyroidism, pheochromocytoma; may cause allergic reactions including angioedema; pregnancy category D.
Risk of ischemic events (peripheral, cardiac, cerebral), fibrosis (retroperitoneal, pulmonary, cardiac), elderly patients (more sensitive to adverse effects), ergotism, drug interactions with CYP3A4 inhibitors, and prolonged use leading to medication-overuse headache.
Hypersensitivity to nicotine or any component; nonsmokers; immediate post-myocardial infarction period; life-threatening arrhythmias; severe or worsening angina pectoris.
Hypersensitivity to ergot alkaloids, peripheral vascular disease, coronary artery disease, uncontrolled hypertension, sepsis, hepatic or renal impairment, pregnancy, breastfeeding, concomitant use with potent CYP3A4 inhibitors, hemiplegic or basilar migraine.
No known food interactions. Avoid concurrent use of retinoid creams or other exfoliating agents that may increase skin sensitivity.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, increasing ergotamine levels and risk of toxicity. No other significant food interactions.
WIGRETTES contains nicotine, which is a known teratogen. First trimester exposure is associated with increased risk of spontaneous abortion, preterm birth, and low birth weight. Second and third trimester exposure can lead to reduced fetal growth, placental complications (e.g., abruption), and potential neurobehavioral effects. The risk is dose-dependent and compounded by maternal smoking.
Ergotamine (ERGOMAR) is contraindicated in pregnancy due to its oxytocic properties and potential for uterine hyperstimulation, fetal hypoxia, and congenital anomalies. First trimester: Increased risk of spontaneous abortion and major malformations (e.g., limb defects, CNS abnormalities) based on case reports. Second and third trimesters: Uterine hypertonicity and decreased placental perfusion leading to fetal distress, preterm labor, and low birth weight. Use only if benefit outweighs risk and no alternative; avoid in all trimesters.
Nicotine is excreted into breast milk with a milk-to-plasma ratio of approximately 2.9. Concentrations can exceed maternal serum levels. Nursing infants are at risk for nicotine absorption leading to irritability, sleep disturbances, and reduced milk intake. Breastfeeding is generally discouraged during nicotine replacement therapy; if used, timing of patches should minimize infant exposure (e.g., remove at night).
Ergotamine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.5-0.9. Potential for ergotism symptoms in infants (vomiting, diarrhea, seizures). It may also reduce milk production due to prolactin inhibition. Contraindicated during breastfeeding per manufacturer guidelines. If exposure occurs, monitor infant for symptoms and consider abrupt cessation.
Pregnancy increases nicotine clearance by approximately 60%, potentially reducing efficacy of standard doses. Higher doses of nicotine replacement therapy may be required to achieve therapeutic effect and prevent withdrawal. However, safety of high-dose NRT in pregnancy is not established. Dose should be individualized based on maternal smoking history and withdrawal symptoms.
Pregnancy may alter ergotamine pharmacokinetics (increased plasma volume, renal clearance, hepatic metabolism), but no established dose adjustment guidelines. Standard doses may be ineffective or toxic due to variable absorption. Avoid use if possible; if necessary, lowest effective dose for shortest duration, with close monitoring for toxicity.
Wigrettes are wax-based hair removal products containing depilatory agents like calcium thioglycolate. For scalp use only; avoid contact with eyes and broken skin. Perform a patch test 24 hours prior to first use. Do not use on irritated or sunburned skin. Overuse may cause chemical burns or allergic contact dermatitis. Duration of application time is critical: typically 5-10 minutes, do not exceed 15 minutes. Remove with a wooden spatula in direction of hair growth. Neutralize residue with water or mild soap.
Ergomar (ergotamine tartrate sublingual tablets) is a first-line abortive therapy for acute migraine attacks, but its use is limited by vasoconstrictive risks. Avoid in patients with coronary artery disease, hypertension, peripheral vascular disease, or pregnancy. Administer at the first sign of migraine; sublingual route offers rapid absorption. Concomitant use with potent CYP3A4 inhibitors (e.g., macrolides, protease inhibitors) is contraindicated due to risk of ergotism. Limit total dose to 6 mg per attack and 10 mg per week.
Read all directions before use.,Do a patch test on a small area of skin 24 hours before use.,Apply only to clean, dry scalp hair; not for eyebrows, eyelashes, or body hair.,Avoid contact with eyes, nose, and mouth. If contact occurs, rinse with plenty of water.,Do not use on sunburned, broken, or irritated skin.,Set a timer; do not leave on longer than directed (usually 5-10 minutes, max 15 minutes).,Remove product gently with the provided spatula in the direction of hair growth.,Rinse scalp thoroughly with water after removal; do not use soap immediately if irritation occurs.,Do not use more than once every 72 hours.,Store in a cool, dry place away from children.
Take one sublingual tablet at the first sign of migraine, placing it under the tongue to dissolve, and do not swallow.,Do not exceed 3 tablets per attack or 5 tablets per week; overuse can lead to serious side effects.,Seek immediate medical attention if you experience symptoms of ergotism like severe coldness, numbness, or pain in hands/feet, muscle cramps, chest pain, or rapid heartbeat.,Avoid grapefruit and grapefruit juice during treatment as it may increase the risk of side effects.,Inform your doctor if you are pregnant, breastfeeding, or have any history of heart disease, high blood pressure, or peripheral artery disease.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WIGRETTES vs ERGOMAR, answered by our medical review team.
WIGRETTES is a Ergot Alkaloid that works by Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.. ERGOMAR is a Ergot Alkaloid Antimigraine that works by Ergotamine acts as a partial agonist at serotonin 5-HT1B and 5-HT1D receptors, causing vasoconstriction of cranial blood vessels. It also inhibits norepinephrine reuptake and has alpha-adrenergic blocking activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WIGRETTES and ERGOMAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WIGRETTES is: 1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.. The standard adult dose of ERGOMAR is: Ergotamine tartrate 1-2 mg sublingually or orally at onset of migraine, then 1-2 mg every 30 minutes as needed, maximum 6 mg per attack and 10 mg per week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WIGRETTES and ERGOMAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WIGRETTES is classified as Category C. WIGRETTES contains nicotine, which is a known teratogen. First trimester exposure is associated with increased risk of spontaneous abortion, preterm birth, and low birth weight. Se. ERGOMAR is classified as Category C. Ergotamine (ERGOMAR) is contraindicated in pregnancy due to its oxytocic properties and potential for uterine hyperstimulation, fetal hypoxia, and congenital anomalies. First trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.